Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Oxford Vaccine Group, part of the University of Oxford Department of Paediatrics, have been successful in gaining funding from the European Vaccine Initiative and the Bill and Melinda Gates Foundation for new research into Salmonella Paratyphii.

The group, who are based in the Centre for Clinical Vaccinology and Tropical Medicine on the Churchill Hospital site, are pleased that this major new funding allows them to launch a new study with the aim of advancing the scientific knowledge of paratyphoid disease and the effect this has on the human immune system in the hope of finding an effective vaccine in the near future.

Salmonella Paratyphi infections cause symptoms similar to typhoid fever, which is becoming an increasing problem in developing countries, particularly in Asia. Although very rare in the UK it can be picked up by travelers in these countries. Paratyphoid infection is responsible for over five million infections each year, mostly affecting children. Although the disease can be treated with antibiotics and could be prevented with access to clean water and sanitation facilities there are still many deaths each year. Despite this a vaccine has not yet been found.

The Oxford Vaccine Group, lead by Professor Andrew Pollard, plan to enrol up to 80 volunteers, who will swallow a drink containing Salmonella Paratyphi bacteria. They will then follow them closely in the subsequent two weeks performing blood, stool (faeces), saliva and urine tests to see how their immune system responds to the bacteria. 

If you are interested in finding out more about this important global health project, visit the study information page.

Similar stories

Promising discovery for treatment of neuromuscular diseases

Research led by Carlo Rinaldi and Catheryn Lim discovered that a naturally-occurring isoform of an androgen receptor can be used in therapy for spinal and bulbar muscular atrophy, and shows potential for other diseases.

University of Oxford researchers among recipients of Ireland and UK joint research awards for digital humanities in €6.5m boost for interdisciplinary research partnerships

Dr Samantha Vanderslott (Oxford Vaccine Group) and Dr Claas Kirchhelle (University College Dublin) have had their three-year project ‘Typhoid, Cockles, and Terrorism’ about the history of typhoid in Dublin successfully funded.

Why we must expand newborn screening

Early diagnosis is of primary importance both to obtain the best effect of innovative medications and to accelerate their development, writes Professor Laurent Servais.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

Oxford vaccine effective against major B.1.1.7 ‘Kent’ coronavirus strain circulating in the UK

A preprint of ongoing work to assess effectiveness of Oxford’s ChAdOx1 coronavirus vaccine shows that the existing vaccine has similar efficacy against the B.1.1.7 ‘Kent’ coronavirus strain currently circulating in the UK to previously circulating variants.

Children’s pain ‘swept under the carpet for too long’ – Lancet Commission

The launch of Lancet Child and Adolescent Health Commission - the first ever to address paediatric pain - aims to raise the profile of children’s pain from early years to early adulthood.